New combo tackles Tough-to-Treat colorectal cancer

NCT ID NCT01715441

Completed Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 21, 2026 · Updated 15 times

Summary

This study tested whether adding the drug sorafenib to irinotecan helps control advanced colorectal cancer in people whose tumors have a KRAS mutation and who have already tried all standard treatments. 173 adults took part. The goal was to see if the combination slowed cancer growth better than irinotecan alone or sorafenib alone. This is a disease control study, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

C.H.U. de REIMS

Reims, 51092, France
CHU Charles Nicolle

Rouen, 76038, France
CRLC Val d'Aurelle-Paul Lamarque

Montpellier, 34298, France
Centre François Baclesse

Caen, 14076, France
Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Hôpital AVICENNE

Bobigny, 93009, France
Hôpital LA TIMONE

Marseille, 13365, France
Institut de Cancérologie de l'Ouest - René Gauducheau

Saint-Herblain, 44805, France

Conditions

Explore the condition pages connected to this study.

METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATED TUMORS